Latest news with #MaximilianFoerst
Yahoo
17-07-2025
- Business
- Yahoo
ZEISS Group Appoints Martin Fischer as President and CEO of ZEISS Greater China
SHANGHAI, July 17, 2025 /PRNewswire/ -- ZEISS Group recently announced that Martin Fischer will officially take on the role of President and CEO of ZEISS Greater China, effective from October 1, 2025, reporting directly to Andreas Pecher, President and CEO of the ZEISS Group. Martin Fischer succeeds Maximilian Foerst, who joined the Executive Board of the ZEISS Group as the President and CEO of Carl Zeiss Meditec AG on June 1, 2025. ZEISS Greater China manages all business activities in China's mainland, Hong Kong SAR, and Taiwan Region. "ZEISS's commitment to Greater China remains strong. China is ZEISS's largest market and is an important cornerstone in its global footprint. I am very pleased that Martin Fischer has agreed to take on this important position," says Andreas Pecher. "Martin is a very experienced leader, who is already quite familiar with ZEISS and our customers. This will ensure a smooth transition as we continue our Greater China strategy that started under Maximilian Foerst's leadership." Martin Fischer joined ZEISS in 2006 and has held positions at various business segments including Semiconductor Manufacturing Technology (SMT), Industrial Quality Solutions (IQS), and Research Microscopy Solutions (RMS). Since 2022, he has been Global Head of Sales, Service & Marketing for RMS. In this position, he has expanded the commercial organization to include marketing and customer experience. He also set up and led various strategically important programs. These have enabled the RMS team to successfully sell agnostic software and enter the future growth markets of biotech & pharma as well as electronics/semiconductors. In addition, he has made important contributions to regional growth projects in the US and APAC, and to the strategic programs for the ZEISS Group. "I am very honored to be appointed as President and CEO of ZEISS Greater China. Maximilian successfully led all the business segments in the region for the past 16 years, laying a solid foundation for future development," said Martin Fischer. "I am excited to lead the Greater China team, which consists of a strong and efficient management team, along with thousands of dedicated and passionate employees. The strategic development of ZEISS Greater China is at the forefront of the Group, and I look forward to achieving more progress in innovation, localization, and all business segments in the future." About ZEISS Group ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the fiscal year 2023/24, the ZEISS Group generated annual revenue totaling nearly 11 billion euros in its four segments: Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (as of 30 September 2024). Currently, 15 percent of revenue is invested in science and R&D. For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars. With a portfolio aligned with future growth areas like digitalization, healthcare and smart production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS's technology and market leadership. Today, around 46,500 employees work at the ZEISS Group globally in around 50 countries. The company is headquartered in Oberkochen (Germany). The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG. Further information available at About ZEISS in Greater China ZEISS' history in Greater China dates to 1957. ZEISS is now represented in the Greater China market with all segments including Semiconductor Manufacturing Technology, Industry Quality & Research, Medical Technology, and Consumer Markets. Since 2021, China has become ZEISS's largest single market in the world, and one of the most innovative and fastest-growing markets. In the fiscal year 2023/24, ZEISS in Greater China generated annual revenue totaling 15.1 billion RMB, with a 12% increase compared to the prior year. Over 7,000 employees throughout the country with more than 60 sites of manufacturing factories, sales & service offices and R&D centers strongly support our customers in the region, and guarantee every related business internationally. The headquarters of ZEISS Greater China is located in Shanghai Pilot Free Trade Zone. It is home to a wide range of activities: China Sales & Service headquarters, competence and training centers, manufacturing facility for the ZEISS Industrial Metrology business group and Shanghai Innovation and R&D Center, ZEISS Group's first corporate innovation and R&D center outside of Germany. ZEISS regional headquarters and the Innovation and R&D Center in Shanghai, together with the Suzhou R&D and Manufacturing Site and Guangzhou Knowledge Manufacturing Base are creating a closed-loop industrial chain that includes medical devices, high-end manufacturing and R&D equipment, and optical lenses. ZEISS is committed to supporting domestic R&D and works closely with Chinese partners to ensure the high-quality and sustainable development of China's cutting-edge industries. Further information available at View original content to download multimedia: SOURCE ZEISS Group
Yahoo
17-07-2025
- Business
- Yahoo
ZEISS Group Appoints Martin Fischer as President and CEO of ZEISS Greater China
SHANGHAI, July 17, 2025 /PRNewswire/ -- ZEISS Group recently announced that Martin Fischer will officially take on the role of President and CEO of ZEISS Greater China, effective from October 1, 2025, reporting directly to Andreas Pecher, President and CEO of the ZEISS Group. Martin Fischer succeeds Maximilian Foerst, who joined the Executive Board of the ZEISS Group as the President and CEO of Carl Zeiss Meditec AG on June 1, 2025. ZEISS Greater China manages all business activities in China's mainland, Hong Kong SAR, and Taiwan Region. "ZEISS's commitment to Greater China remains strong. China is ZEISS's largest market and is an important cornerstone in its global footprint. I am very pleased that Martin Fischer has agreed to take on this important position," says Andreas Pecher. "Martin is a very experienced leader, who is already quite familiar with ZEISS and our customers. This will ensure a smooth transition as we continue our Greater China strategy that started under Maximilian Foerst's leadership." Martin Fischer joined ZEISS in 2006 and has held positions at various business segments including Semiconductor Manufacturing Technology (SMT), Industrial Quality Solutions (IQS), and Research Microscopy Solutions (RMS). Since 2022, he has been Global Head of Sales, Service & Marketing for RMS. In this position, he has expanded the commercial organization to include marketing and customer experience. He also set up and led various strategically important programs. These have enabled the RMS team to successfully sell agnostic software and enter the future growth markets of biotech & pharma as well as electronics/semiconductors. In addition, he has made important contributions to regional growth projects in the US and APAC, and to the strategic programs for the ZEISS Group. "I am very honored to be appointed as President and CEO of ZEISS Greater China. Maximilian successfully led all the business segments in the region for the past 16 years, laying a solid foundation for future development," said Martin Fischer. "I am excited to lead the Greater China team, which consists of a strong and efficient management team, along with thousands of dedicated and passionate employees. The strategic development of ZEISS Greater China is at the forefront of the Group, and I look forward to achieving more progress in innovation, localization, and all business segments in the future." About ZEISS Group ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the fiscal year 2023/24, the ZEISS Group generated annual revenue totaling nearly 11 billion euros in its four segments: Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (as of 30 September 2024). Currently, 15 percent of revenue is invested in science and R&D. For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars. With a portfolio aligned with future growth areas like digitalization, healthcare and smart production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS's technology and market leadership. Today, around 46,500 employees work at the ZEISS Group globally in around 50 countries. The company is headquartered in Oberkochen (Germany). The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG. Further information available at About ZEISS in Greater China ZEISS' history in Greater China dates to 1957. ZEISS is now represented in the Greater China market with all segments including Semiconductor Manufacturing Technology, Industry Quality & Research, Medical Technology, and Consumer Markets. Since 2021, China has become ZEISS's largest single market in the world, and one of the most innovative and fastest-growing markets. In the fiscal year 2023/24, ZEISS in Greater China generated annual revenue totaling 15.1 billion RMB, with a 12% increase compared to the prior year. Over 7,000 employees throughout the country with more than 60 sites of manufacturing factories, sales & service offices and R&D centers strongly support our customers in the region, and guarantee every related business internationally. The headquarters of ZEISS Greater China is located in Shanghai Pilot Free Trade Zone. It is home to a wide range of activities: China Sales & Service headquarters, competence and training centers, manufacturing facility for the ZEISS Industrial Metrology business group and Shanghai Innovation and R&D Center, ZEISS Group's first corporate innovation and R&D center outside of Germany. ZEISS regional headquarters and the Innovation and R&D Center in Shanghai, together with the Suzhou R&D and Manufacturing Site and Guangzhou Knowledge Manufacturing Base are creating a closed-loop industrial chain that includes medical devices, high-end manufacturing and R&D equipment, and optical lenses. ZEISS is committed to supporting domestic R&D and works closely with Chinese partners to ensure the high-quality and sustainable development of China's cutting-edge industries. Further information available at View original content to download multimedia: SOURCE ZEISS Group Sign in to access your portfolio
Yahoo
26-02-2025
- Business
- Yahoo
ZEISS VISUMAX 800 with SMILE pro software receives approval in China
Updated ZEISS femtosecond laser provides refractive surgeons in China with faster treatment, greater flexibility, and significant workflow JENA, Germany and SHANGHAI, Feb. 26, 2025 /CNW/ -- ZEISS Medical Technology announced today that the National Medical Products Administration (NMPA) in China has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism. The latest generation of femtosecond lasers from ZEISS enters the China market at a time when more than 10 million eyes have been treated with ZEISS SMILE and SMILE pro worldwide, reflecting the technology's broad global momentum driven by strong adoption in Asia, Europe and the U.S. "With the growing interest in laser vision correction in China, the market needs innovative technology that enhances surgical outcomes, safety and efficiency to benefit both surgeons and their patients. The availability of the ZEISS VISUMAX 800 with SMILE pro software further extends our commitment to ophthalmologists and helps to solidify the future of laser vision correction across China," says Maximilian Foerst, Head of ZEISS Greater China. "ZEISS further sets itself apart in the China market with the availability of the VISUMAX 800 with SMILE pro software from ZEISS, providing the latest digital technology to meet the evolving needs of refractive surgeons worldwide," said Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "This next-generation femtosecond laser system creates data-driven insights to help surgeons better manage treatment paths for patients while supporting each surgeon's unique practice requirements for greater workflow efficiency and performance." The VISUMAX® 800 with SMILE® pro software from ZEISS enables faster treatment, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz.* Additionally, the shorter procedure time can reduce stress for surgeons and their patients. The ZEISS femtosecond laser also provides greater flexibility for the surgeon and patient, with a smaller footprint and compatibility with a variety of patient beds, adapting to the clinical environment to provide cutting-edge technology without compromise. With the availability of the VISUMAX® 800 with SMILE® pro software from ZEISS in China, surgeons can utilize a number of workflow enhancements including: the CentraLign® centration aid, a computer-controlled function for easy centration; the OcuLign® cyclotorsion adjustment to help counter cyclotorsion that may occur; and VISULYZE user nomograms to help surgeons collect and analyze patient data, while also providing detailed nomograms and enabling more control during every surgery. With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX® 800 with SMILE® pro software from ZEISS offers substantial market opportunities for surgeons in China. For more information about the VISUMAX® 800 with SMILE® pro software from ZEISS, visit * Data on file, myopia with optical zone 6.5 mm. Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. Contact for investorsSebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: Contact for the pressFrank SmithHead of Global Communications OphthalmologyCarl Zeiss Meditec +49 3641 220 331Mail: View original content to download multimedia: SOURCE Carl Zeiss Meditec AG View original content to download multimedia: Sign in to access your portfolio
